Calithera Biosciences, Inc. (CALA)

Market Cap	1.78M
Revenue (ttm)	n/a
Net Income (ttm)	-84.93M
Shares Out	4.87M
EPS (ttm)	-26.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	782,291
Open	0.400
Previous Close	0.410
Day's Range	0.303 - 0.400
52-Week Range	0.303 - 13.380
Beta	1.33
Analysts	Buy
Price Target	5.10 (+1,296.88%)
Earnings Date	Mar 29, 2023

About CALA

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chro...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 2, 2014
• Employees: 63
• Stock Exchange: NASDAQ
• Ticker Symbol: CALA

Analyst Forecast

According to 10 analysts, the average rating for CALA stock is "Buy." The 12-month stock price forecast is $5.1, which is an increase of 1,296.88% from the latest price.

Price Target

$5.1

(1,296.88% upside)

Analyst Consensus: Buy